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are elucidating the nature and neural substrates of cognitive changes associated with various
cannabinoids. Long-term or heavy cannabis use appears to result in longer-lasting cognitive
abnormalities and possibly structural brain alterations. Greater adverse cognitive effects are associated
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Cognitive abnormalities and cannabis use
Anormalidades cognitivas no uso da cannabis
Nadia Solowij,1,2 Nicole Pesa1
1
2

School of Psychology, University of Wollongong, Wollongong, Australia
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Abstract
Objective: Evidence that cannabis use impairs cognitive function in
humans has been accumulating in recent decades. The purpose of this
overview is to update knowledge in this area with new findings from
the most recent literature. Method: Literature searches were conducted
using the Web of Science database up to February 2010. The terms
searched were: “cannabi*” or “marijuana”, and “cogniti*” or “memory”
or “attention” or “executive function”, and human studies were reviewed
preferentially over the animal literature. Discussion: Cannabis use
impairs memory, attention, inhibitory control, executive functions
and decision making, both during the period of acute intoxication and
beyond, persisting for hours, days, weeks or more after the last use of
cannabis. Pharmacological challenge studies in humans are elucidating
the nature and neural substrates of cognitive changes associated with
various cannabinoids. Long-term or heavy cannabis use appears to result
in longer-lasting cognitive abnormalities and possibly structural brain
alterations. Greater adverse cognitive effects are associated with cannabis
use commencing in early adolescence. Conclusion: The endogenous
cannabinoid system is involved in regulatory neural mechanisms that
modulate processes underlying a range of cognitive functions that are
impaired by cannabis. Deficits in human users most likely therefore
reflect neuroadaptations and altered functioning of the endogenous
cannabinoid system.

Resumo
Objetivo: Evidências de que o uso de cannabis prejudica funções cognitivas
em humanos têm-se acumulado nas décadas recentes. O propósito desta revisão
é o de atualizar o conhecimento nesta área com novos achados a partir da
literatura mais recente. Método: As buscas na literatura foram realizadas
utilizando-se o banco de dados Web of Science até fevereiro de 2010. Foram
buscados os termos “cannabi*” ou “marijuana” e “cogniti*” ou “memory”
ou “attention” ou “executive function”, e os estudos em humanos foram
revisados preferencialmente em relação aos estudos em animais. Discussão:
O uso de cannabis prejudica a memória, a atenção, o controle inibitório, as
funções executivas e a tomada de decisões, tanto durante como após o período
de intoxicação aguda, persistindo por horas, dias, semanas ou mais após o
último uso. Os estudos de desafio farmacológico em humanos estão elucidando
a natureza e os substratos neurais das alterações cognitivas associadas a vários
canabinoides. O uso pesado ou de longo prazo de cannabis parece resultar
em anormalidades cognitivas mais duradouras e possivelmente em alterações
cerebrais estruturais. Efeitos cognitivos adversos maiores estão associados ao
uso de cannabis quando este começa no início da adolescência. Conclusão:
O sistema canabinoide endógeno está envolvido nos mecanismos de regulação
neural que modulam os processos subjacentes a uma gama de funções cognitivas
que estão prejudicadas pela cannabis. Os déficits em usuários humanos muito
provavelmente refletem, portanto, neuroadaptações e o funcionamento alterado
do sistema canabinoide endógeno.

Descriptors: Cannabis; Cannabinoids; Cognition; Physiological
processes/drug effects; Neurobehavioral manifestations

Descritores: Cannabis; Canabinoides; Cognição; Processos fisiológicos/efeitos
de drogas; Manifestações neurocomportamentais

Introduction
Concerns regarding the adverse consequences of cannabis use
continue to grow. This is well founded given that cannabis is the
most widely used illicit substance in the world, with use often
beginning in adolescence, a key period for neural and psychosocial
development.
While the cognitively impairing effects of cannabis during
acute intoxication have been acknowledged for some time, an
accumulating body of evidence indicates that long-term or heavy

cannabis use results in definite but subtle cognitive impairments
that persist beyond the period of acute intoxication. The extent
to which such deficits persist in the longer-term remains a
controversial area for debate within the field of human cannabis
research. Some studies demonstrate cognitive dysfunction in
cannabis users during intoxication and for several hours following
smoking,1,2 others show impairment for a few days,3,4 and yet
others have shown lasting impairments for more than a month
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following cessation of use.5 Understanding the persistence of
cognitive deficits associated with cannabis use is not a simple
matter of organising the literature by cognitive domains to
determine which kinds of tasks may elicit shorter- or longerlasting effects of cannabis, because comparisons across studies are
very much confounded by varying levels of exposure to cannabis
(if not other substances as well). Elucidating the nature and
extent of cognitive dysfunction resulting from cannabis use will
require significant further research to determine the parameters
of use that result in cognitive deficits across a range of tasks and
cognitive domains.
Various parameters of cannabis use and their relationship to
cognitive impairment can be examined when looking at deficits
that persist for a period of 24 hours or longer. Relationships
between cognitive performance and frequency of cannabis use
may indicate a residual effect of acute or chronic intoxication
that would likely dissipate with the reduction or cessation of use.
Associations with the dose of cannabis used might similarly reflect
a residual effect, or in the case of cumulative dose of exposure, may
indicate more enduring dose-related brain changes. Associations
with duration of use imply a more enduring impairment,
rather than one resulting from cannabinoid residues, and one
which likely reflects actual alterations to brain function over
the long term and gradual neuroadaptation. The age of onset of
cannabis use has received much attention in recent years. This is
in light of evidence that the age of initiation of cannabis use is
decreasing,6-9 with concerns regarding exposure during the critical
neurodevelopmental period of early adolescence and a recognition
that the adolescent brain is more susceptible to drug insult.10
The extent to which cognitive deficits resulting from cannabis
may be reversible upon cessation of use is inconclusive. One study
suggests function is recovered within one month of abstinence,3
another study indicates that recovery does not occur after 28 days
of monitored abstinence,5 and others suggest that partial recovery
may occur.11,12 With the recent reporting of regional structural
brain changes in long-term heavy cannabis users (reduction
in hippocampal and amygdala volumes),13 research has yet to
examine the extent to which such alterations may be reversible
with abstinence.
Cognitive impairment in cannabis users is most often detected in
memory, attention and inhibitory control and executive functions.
There is no doubt that the endogenous cannabinoid system plays
a critical role in these functions and that their disruption by acute
cannabis administration is cannabinoid receptor (CB1) mediated.
Novel and specific roles of different cannabinoids in cannabis plant
matter [eg. THC versus cannabidiol (CBD)] are increasingly being
elucidated. We have previously reviewed the literature to 2007 in
the context of the similarity between cognitive deficits in cannabis
users and those observed in schizophrenia14 and as specific to
memory function.15 This paper will update our knowledge with
evidence from the most recent studies of cognitive function in
human users with a focus on the long-term effects of cannabis use.
We also consider recent research elucidating the effects of acute
cannabis administration in humans, studies of brain structure and

function, and in brief, evidence from animal studies of acute and
chronic administration of cannabinoids. We group the studies
reviewed according to the primary cognitive domains identified
as being affected by cannabis: attention, inhibition, working
memory/executive functions and verbal memory.
Method
Literature searches were conducted using the Web of Science
database from January 2007 through February 2010 to update
previous reviews performed by the authors with select literature to
incorporate in this specific overview of the area. The terms searched
were: “cannabi*” or “marijuana” and “cogniti*” or “memory” or
“attention” or “executive function” and human literature was
reviewed preferentially over animal literature.
Discussion
1. Acute effects on human cognition
During the acute intoxication, cannabis induces perceptual
distortions, and impairs memory and concentration. Recent years
have seen a revival of interest in examining the acute effects of
cannabinoids on cognition in humans, with greater application of
prospective, double-blind, placebo-controlled cross-over designs,
and with particular interest in relation to understanding the
psychotomimetic effects of cannabis.
A range of attentional processes are impaired by cannabis
acutely. Impaired performance on sustained attention (eg. on
continuous performance tasks), selective, focused and divided
attention tasks, as well as in preattentive sensory memory have
been demonstrated following acute doses of cannabis (THC or
cannabis extract) to humans.16-19 Impaired performance, in terms
of accuracy, increased error rates and slowed reaction times, has
been shown to be dose-related in some studies.18 Tolerance may
develop to some of the acute effects of cannabis in regular users.
For example, Ramaekers et al. found impaired performance on
a divided attention task following high dose 500μg/kg THC
only in occasional but not heavy users, whereas both occasional
and heavy users exhibited inhibitory control deficits in a Stop
Signal task.19 Altered inhibitory processing is evident following
acute intoxication, in particular through impulsive responding.20
Hart et al. found evidence of a greater incidence of premature
responding during acute intoxication in a range of tasks, discussing
this in terms of failures of inhibitory control over inappropriate
responses.21 Acute administration of THC increased impulsive
responding on a Stop Signal Task, but did not affect Go/NoGo
task performance in one study,20 although McGuire et al. showed
in an imaging study that THC attenuated activation in the right
inferior frontal cortex during a Go/NoGo task.22
O’Leary et al. showed that 20mg of THC had dramatic effects
in occasional cannabis users on regional cerebral blood flow during
the performance of a dichotic auditory selective attention task,
but that these changes were not task-related.17 Acute effects of
cannabinoids on electrophysiology have been demonstrated in
infrequent cannabis users for the mismatch negativity (MMN)
component of the event-related potential (ERP) (MMN being
Revista Brasileira de Psiquiatria • vol 32 • Suppl I • may2010 • S32
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an index of preattentive sensory memory) 23 and the P300
component (an index of the allocation of attentional resources
and updating of memory traces).24 Interestingly, Juckel et al.23
found no effect of a relatively low dose of THC alone (10mg) on
the mismatch negativity but an enhancement of the component
when THC was co-administered with 5.4mg CBD, pertinent
to the proposed antipsychotic properties of CBD. Mismatch
negativity is diminished in people with schizophrenia.25,26 On
the other hand, Roser et al.24 showed with the same doses that
both THC alone and THC with CBD reduced the auditory P300
amplitude, which is also known to be reduced in schizophrenia
and other clinical populations.
D’Souza et al. conducted a rigorous investigation of the effects
of intravenous THC administered to healthy volunteers who had
experience with cannabis use but who were not heavy users.27
THC induced transient positive and negative schizophrenialike symptoms and impaired working memory, verbal memory,
distractibility and verbal fluency. Similarly, Morrison et al. report
induction of positive psychotic symptoms and deficits in verbal
episodic memory and executive function following administration
of intravenous THC.28 Short-term memory problems are among
the most frequently self-reported consequences of cannabis use by
individuals who use the drug and are commonly reported reasons
for seeking to quit or reduce cannabis use. Deficits in verbal
learning and memory are perhaps the most robust impairments
associated with acute cannabis use2,16,27-29 and impaired immediate
and delayed free recall of information was emphasised in one recent
review of the acute effects of cannabis on memory function,29 while
another described evidence for difficulties in manipulating the
contents of working memory, failure to use semantic processing
and organisation to optimise episodic memory encoding, and
impaired retrieval performance.30
Ilan et al. found that acute intoxication resulted in greater
intrusion errors during recognition memory, and those subjects who
were most affected by cannabis showed a reduced ERP difference
between previously studied words and new distractor words,
suggesting a disruption of neural mechanisms underlying memory
for recent study episodes.16 Curran et al.2 found that a high dose
of THC (15mg) resulted in no learning occurring over a 3-trial
selective reminding task, while Bhattacharyya and McGuire et al.
reported a series of neuroimaging studies of the effects of orally
administered 10mg THC or 600mg CBD on the neural bases
of verbal learning.22,31,32 They found that the effects of cannabis
on verbal learning were mediated through its influence on left
temporal activity (particularly parahippocampal), with modulation
also of medial prefrontal and anterior cingulate activity, during
encoding or retrieval of information. These studies also elucidated
the neural basis of the anxiogenic or anxiolytic effects of THC and
CBD, respectively, as pertinent to understanding the propensity for
cannabis to induce psychotic symptoms. Other recent neuroimaging
studies of acute administration effects of cannabioids have been
reviewed by Martin-Santos et al.33
Working memory is disrupted by acute cannabis use.16,27,34
Performance, electroencephalogram (EEG), and ERP measures
S33 • Revista Brasileira de Psiquiatria • vol 32 • Suppl I • may2010

were impaired on a spatial n-back task after smoked cannabis,16
and acute administration of THC impaired delay-dependent
discrimination within working memory in a delayed matching
to sample task.34 Conversely, in another study, acute THC
administration was found to spare working memory but impair
episodic memory in infrequent cannabis users, with no residual
effects 24 or 48 hours later.21 Regular but infrequent cannabis
users showed dose-dependently impaired performance (greater
errors) on a Sternberg memory task following acute administration
of THC17 and these have been associated with reduced frontalmidline EEG theta power.35
Thus, further evidence has accumulated for a disruption
of attention, memory, and inhibitory control following acute
administration of cannabis to humans, with some elucidation
of the neural substrates of these effects, including evidence of
differential effects of different cannabinoids (such as THC and
CBD). It appears also that the response to acute cannabinoid
administration is mediated by cannabis use history and the
development of tolerance to the acute effects in some cognitive
tasks, but insufficient research has determined in any systematic
way the parameters of cannabis use that lead to the development
of tolerance, the doses that may or may not elicit impaired
performance in regular users, or the cognitive tasks that are
amenable to tolerance. For example, Boucher et al. showed that
impairments in spatial working memory in rats are resistant
to tolerance after extended administration of THC.36 Nor has
research determined whether or how regular users may develop
compensatory strategies during the acute intoxication to facilitate
performance that might otherwise be impaired. For example, in
a risky decision-making task, Rogers et al. showed a reduction of
risky behaviour following low dose sublingual administration of
THC to healthy young adults (not regular cannabis users), with
an adoption of more cautious cognitive strategies to compensate
for the perceived disruption of effective decision making by
cannabis.37 Regular users, due to their greater experience with
cannabis, might be more likely to develop alternate compensatory
strategies, but this hypothesis remains to be tested. Another study
of decision making as assessed by the Iowa Gambling Task found
no disruption to risky behaviour, only a slowing of performance,
in daily cannabis users during acute intoxication.38
2. Long-term effects on human cognition
Studies of long-term and heavy cannabis users, tested in the
unintoxicated state, have continued to investigate residual or
persistent effects of cannabis on cognitive function, with gradually
greater control over confounds, and more attention to the
parameters of cannabis use.
1) Attention
Sustained attention, most often measured by continuous
performance tasks (CPTs), is inconsistently impaired. Pope et
al. found performance on CPTs to be insensitive to chronic
cannabis use in adults,3 but Jacobsen et al. found that adolescent
cannabis users made significantly more errors than non-using
controls and increased errors trended toward an association
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with greater exposure to cannabis.39 A recent study examined
sustained attention in 132 long-term cannabis users divided into
an early onset group (those who had commenced cannabis use
prior to the age of 15 years) and a late onset group (≥ 15 years).40
Early onset users performed significantly worse on the sustained
attention task, with no performance differences between the late
onset group and controls. However, even in the absence of overt
performance deficits, lower glucose metabolism in orbitofrontal,
temporal, hippocampal and parahippocampal regions was
observed during CPT performance in regular cannabis users.41 A
study of preattentive pre-pulse inhibition (PPI) attributed poor
performance by chronic cannabis users to deficits in sustained
attention, which were also associated with greater frequency of
cannabis use.42
Selective and divided attention deficits in chronic cannabis
users have been shown to be related to duration, frequency,
and age of onset of use.11,12,43-48 Long-term users have difficulty
filtering out irrelevant information, a deficit that became more
pronounced the longer that cannabis had been used.11,12,43,44,46
Further, only partial recovery was evident after a mean abstinence
period of two years and no improvement with increasing months
of abstinence, suggesting partial recovery may occur relatively
soon after cessation of use and enduring impairment may reflect
longer-lasting neuroadaptations.11,12 Early onset of cannabis use
(i.e. prior to 16 years) was a strong predictor of attentional deficits
during adulthood,47 and even relatively light use of once a week was
related to some attentional dysfunction in young adults.48 Heavy
users also showed a slowing of information processing during
selective attention, as indexed by the P300 component which
became increasingly delayed the more frequently that cannabis
was used.44,46 This research provided evidence of differential
deficits associated with frequency versus duration of cannabis
use, reflecting shorter- versus longer-lasting effects.44,46 P300
amplitude, thought to reflect the allocation of attentional resources
and reflect inhibitory processes, has also been found to be reduced
in early onset users,49 as well as in adult cannabis users.43,46
2) Inhibition
As cited above under acute effects, impaired inhibitory
processing can be assessed through behavioural tasks such as the
Stroop, Go/NoGo and a variety of decision-making and gambling
tasks, and is also impaired in long-term cannabis users.4,5,50-55
Such tasks require the selection of an appropriate response whilst
simultaneously inhibiting the inappropriate response. It has
been suggested that the endocannabinoid system may modulate
dopaminergic prefrontal cortical and accumbal activity and
contribute to inappropriate incentive salience to irrelevant stimuli,
which may underlie attentional and inhibitory processing and
decision-making deficits.14,56,57 Imaging studies show altered
dorsolateral prefrontal cortical (DLPFC) and anterior cingulate
(ACC) activation during the interference condition of the Stroop
Task, despite reasonable task performance in cannabis users54 and
1-month abstinent cannabis users.50 Performance on the Stroop
task is inconsistently impaired in chronic cannabis users,3-5,40,46 but

poorer performance has been associated with various parameters of
use (duration, dose, early onset)4,5,40,58 that may interact with low
IQ,5 and with altered electrophysiology.58 Similarly, in a Go/NoGo
task, adolescent cannabis users’ task performance was adequate
following one month abstinence, however altered activation was
observed in frontal and parietal brain regions, with users requiring
increased neural effort during the inhibition condition to maintain
performance levels.59 In chronic adult users also with adequate
inhibitory control performance, commission errors increased and a
diminished capacity for behaviour monitoring and error-awareness
was associated with hypoactivity in the ACC and right insula.55
3) Working memory and other executive functions
Working memory is the temporary encoding and manipulation
of information that is a core component of executive functions of
cognition; the involvement of the cannabinoid system in working
memory has been well documented.14,57 Executive function tasks
have been found to be impaired in both acute and chronic cannabis
use (e.g. verbal fluency, Wisconsin Card Sorting Task, Ravens
Progressive Matrices, Tower of London),3-5,60-62 but few studies have
addressed working memory directly in cannabis users and this is an
area that is receiving increasing interest. Both adolescent and adult
chronic cannabis users have shown impaired working memory
on several measures from the Cambridge Neuropsychological
Test Automated Battery (CANTAB) including Rapid Visual
Information Processing, Pattern Recognition Memory, Spatial
Recognition Memory, Spatial Span, Spatial Working Memory
and Visuospatial Paired Associate Learning.63,64 Impairments in
visuospatial working memory may in part be due to deficits in basic
temporal processing of saccades during oculomotor function.65
Performance on an n-back auditory working memory task was
shown to be impaired as memory load increased in abstinent
adolescent cannabis users, with some evidence of altered regional
brain activation emerging during nicotine withdrawal.66 Other
tasks such as the Sternberg working memory task have shown no
performance deficits in abstinent adolescents or young adults,
but altered regional brain activation (prefrontal and parietal)
that was related to task novelty, as opposed to practice, was
reflective of greater effort being required to achieve the task.67,68
Further neuroimaging studies indicate that cannabis users recruit
additional brain regions in a compensatory manner in order to
achieve adequate performance on working memory tasks.33,69,70
In a recent study of verbal fluency, a task that relies heavily on
executive functions, McHale et al. found that young adult cannabis
users with recent use in the past week generated fewer words than
those abstinent for at least one week, and both generated fewer
words than non-user controls.62 The authors suggested some
recovery of cognitive ability with abstinence, but this may have
been confounded by frequency of use as the abstinent group
comprised twice/weekly users, whereas users in the recent use
group smoked 5-6 times/week.
4) Verbal memory and other memory processes
Verbal memory is consistently impaired in chronic cannabis
users, with significantly impaired performance on word list
Revista Brasileira de Psiquiatria • vol 32 • Suppl I • may2010 • S34
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learning tasks (e.g. Rey Auditory Verbal Learning Task (RAVLT),
the California Verbal Learning Task (CVLT), and Buschke’s
Selective Reminding Task).4,5,46,60,71-73 These studies have been
extensively reviewed elsewhere, together with some early
neuroimaging studies of verbal memory in cannabis users.14,15,46,73,74
Overall, the evidence suggests that long-term or heavy cannabis
users show impaired encoding, storage, manipulation and
retrieval mechanisms.15 Users learn fewer words across trials and
recall fewer words particularly after interference or delay. Several
studies have shown that these deficits are variously attributed to
duration of cannabis use,4 frequency of use,3 or cumulative dosage
effects.5 Some studies have shown recovery of memory function
following a period of 28 days abstinence,3 others have shown
that such deficits persist after this period,5 while others suggest
at least partial recovery (Solowij, unpublished data). In the study
that showed recovery, this was less apparent when cannabis use
was commenced at an early age.61 Verbal memory was found
to be impaired in adolescent cannabis users63 and minimum 23
day-abstinent adolescents and associated with lifetime episodes of
use.75 Prospective memory has been demonstrated to be impaired
in adolescent76 and young adult users,62,76 particularly time-based
prospective memory.62
Recent neuroimaging studies have sought to elucidate the acute
effects of THC and other cannabinoids (eg. CBD) on neural
substrates subserving verbal memory, as discussed above,32,33 or
attempted to relate brain structural changes in cannabis users
to verbal memory deficits. For example, Yücel et al. found
significantly reduced hippocampal volumes in long-term heavy
cannabis users, who were also significantly impaired on the RAVLT,
but memory performance was unrelated to hippocampal volumes.13
Such complex verbal learning tasks likely involve functional
connectivity across a wide range of brain regions, and impaired
performance is likely to be associated more with the functional
activation of those regions, rather than their structure. A recent
electrophysiological study in chronic users found poor word
recall and alteration of the ERP subsequent memory effect during
encoding, a component thought to originate in the hippocampal
region, and this alteration was associated with a longer duration
of cannabis use and an earlier onset of use.77
More specific hippocampal-dependent tasks, such as pictorial
associative memory tasks, have also been investigated in one
week abstinent cannabis users.78,79 Task performance did not
differ between moderately-using young adults and non-user
controls but recall accuracy decreased as a function of exposure to
cannabis, and decreased activation was observed in users in bilateral
parahippocampal regions and in the right DLPFC during learning.78
However, a study of adolescents found increased activation in the
fusiform/parahippocampal area, inferior frontal gyrus, DLPFC,
superior parietal cortex and the ACC,79 suggestive of increased
neural effort. A study of hippocampal-dependent face-name learning
in young adult frequent users found impaired learning, short- and
long-term memory, and hypoactivation of frontal and temporal
regions with concomitant hyperactivation of parahippocampal
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regions during learning, reflective of both functional deficits and
compensatory processes.80 When different studies have shown
hypoactivation or hyperactivation in the same regions during
performance of similar tasks (eg. Stroop),50,54 this may be due to
variable parameters of cannabis use, such as the extent of exposure
or age of onset, but further research is required to understand when
and under what conditions increased or decreased activation is likely
to manifest as well as the extent to which other brain regions are
recruited to compensate for inefficiency.
5) Other cognitive functions
Cannabis alters the perception of time, both during the acute
intoxication and in some studies of chronic users.4,21,46,57 Typically,
time is underestimated – the subjective experience is of time
passing more slowly. Time estimation involves the ability to judge
and plan the temporal order of behavioural events in order to allow
the successful adaptation of behaviour.57 These processes may be
underpinned by cannabinoid modulation of cortical glutamatergic
and striatal dopaminergic transmission, and the neural substrates
implicated include the cerebellum, basal ganglia, prefrontal cortex,
and parietal cortex.57 Chronic cannabis users have been shown
to be impaired in a classical delayed eye-blink conditioning task
that reflects cerebellar functional integrity (cerebellar-dependent
associative learning),81 and recent data suggest cerebellar structural
alterations in chronic cannabis users.82
Since cannabis alters mood during the acute intoxication,
interest has grown in examining emotion and affect processing
in chronic cannabis users. Gruber et al. examined regional brain
activation to masked affective stimuli in heavy cannabis users
and found altered frontal and limbic activity, with decreased
activation of anterior cingulate and amygdala regions compared
to controls, and differential effects for masked happy versus angry
faces.83 Two studies of acute cannabis administration also found
modulation of amygdala activity during processing of fearful
faces.84,85 We reported significantly reduced amygdala volumes in
long-term heavy cannabis users13 but it is not yet known whether
this is associated with emotional or affect processing deficits.
Altered affective processing may pose difficulties for effective
communication and decision making, particularly if cingulate
driven inhibition of inappropriate emotional responses became
problematic. Other recent neuroimaging research has examined
reward processing mechanisms in chronic users, showing increased
cerebellar and ventrostriatal activation during reward anticipation,
of which the latter was correlated with the duration of cannabis
use and lifetime dose of exposure.86 In a study of neural activation
underlying motor function, chronic cannabis users showed
diminished activity of the supplementary motor cortex and area
BA32, persisting after 28 days of abstinence, despite adequate
response execution,87 indicating incomplete recovery of optimal
motor planning and execution.
3. Brain structure and function
Evidence for structural brain changes in cannabis users has
been lacking: a number of studies have found no or few global
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or regional changes in brain tissue volume or composition,78,88,89
but some found grey and white matter density changes globally90
or in parahippocampal areas.91 In a recent review92 we examined
the evidence for structural brain alterations in cannabis users and
found that of 13 studies, the majority using MRI, the evidence
was inconsistent. Where differences were found between users and
non-users, they were most apparent in association with greater
dose of exposure to cannabis and were most often localised to the
hippocampal region.
Using more sensitive measures and assessing cannabis users
with far greater exposure to cannabis than previous studies, a
recent study from our own group13 found significant reduction
of bilateral hippocampal (12%) and amygdala (7%) volumes in
adults with a mean 20 years of near daily use compared to age,
gender, and IQ matched non-user controls. The reduction of left
hippocampus was dose-related, correlating with the cumulative
dose of exposure to cannabis over the past 10 years, suggesting a
causal effect. These results accord with evidence of hippocampal
toxicity from the animal literature where animals were exposed to
similar large doses over comparable proportions of their lifespan
and showed decreases in neuronal volume, neuronal and synaptic
density, and dendritic length of CA3 pyramidal neurons.93-96 That
the cannabis users of our study had used three times more cannabis
over their lifespan than those of a study of users with a similar
duration of use but no hippocampal alteration observed,97 suggests
that there may a threshold of cumulative exposure beyond which
these changes in the brain may manifest.
Age of onset of cannabis use may also be a critical factor, with
potentially greater deleterious effects to the brain when cannabis
use is commenced during significant periods of neurodevelopment,
such as adolescence. Early onset cannabis users (before age 17)
were found to have smaller whole brain volumes, lower percent
cortical grey matter, higher percent white matter and increased
cerebral blood flow compared to later onset users.90 A recent study
has reported altered cortical gyrification in the frontal lobe and
abnormal age-related changes to gyrification and cortical thickness
in adolescent and young adult users.98
Several studies have now reported on diffusion tensor imaging
(DTI) measures of white matter structural integrity in cannabis
users. Two studies found few differences between cannabis users
and controls,54,99 whereas increasing evidence for pathology
has come from more recent studies of young adult100,101 and
adolescent102,103 cannabis users, in the corpus callosum and various
fronto-temporal, occipito-frontal and posterior connections that
develop during adolescence. It is suggested that cannabis use,
particularly during adolescence, may affect the trajectory of normal
brain maturation resulting in white matter aberrations, which may
underlie compromised cognitive processing. We have also reported
cerebellar white matter reduction in adult long-term heavy users.82
Further evidence of diminished neuronal and axonal integrity
comes from a magnetic resonance spectroscopic study showing
dose-related changes in DLPFC, ACC and putamen/globus
pallidum, but not hippocampus.104 Changes in regional cerebral

blood volume during 28 days of supervised abstinence have been
reported, with some evidence for frontal normalisation with
continued abstinence, but persistence of alterations in temporal
and cerebellar regions.105 Acute and chronic effects of cannabis
have also been examined on levels of nerve growth factor and
brain-derived neurotrophic factor (BDNF) in serum, showing
some evidence of lowered resting levels in cannabis users,106,107
and cannabinoid modulation of these proteins is evident from a
growing number of preclinical studies.
4. Animal research
A wealth of preclinical research now shows an unequivocal role
for the endogenous cannabinoid system in attention, memory,
executive functions, inhibitory control, and multiple other
cognitive processes, and that these are impaired following both
acute and chronic cannabinoid administration.14,57,108,109 Even
a single administration of an ultra-low dose of THC (0.0010.002mg/kg) has been shown to result in long-term cognitive
impairments in mice (3 weeks to 4 months post-injection).110,111
Animal studies support the notion that the developing brain
is more susceptible to the acute and chronic effects of exogenous
cannabinoids, particularly the hippocampus.112-114 Evidence
is building from studies in which animals have been exposed
prenatally or during the pubertal/adolescent period, with greater
immediate adverse effects on cognition and behaviour observed
in comparison to animals exposed during adulthood, as well as
such effects persisting into adulthood with no further cannabinoid
exposure.10,112-117
Cannabinoid effects are prominent in the hippocampus118,119
and depend on interactions with GABA(A) receptors.120 Further,
modulatory mechanisms of the endocannabinoid system on
prefrontal cortical and striatal dopamine and glutamate transmission
are strongly supported by preclinical evidence.57 In line with human
studies, potentiation and antagonism of cannabinoid-induced
spatial working memory deficits in rats have also been shown to be
dependent on the ratio between THC and CBD.121
Conclusion
There is good evidence now that long-term heavy cannabis
use results in cognitive deficits that have been shown to increase
as a function of frequency, duration, dose, and age of onset of
cannabis use. There is growing recognition that cannabis users
are impaired on many of the same types of cognitive tests on
which people with schizophrenia are also impaired,14 and recent
research has sought to elucidate the neural substrates of impaired
cognition during acute intoxication. These research directions
will inform the mechanisms by which cannabis may trigger
psychotic symptoms or episodes, as the association between
cannabis use and schizophrenia is compelling122,123 and considered
a significant public health concern. The endogenous cannabinoid
system is altered in schizophrenia124,125 but insufficient research
has addressed the nature of alterations to this system following
chronic cannabis use in otherwise healthy humans.
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The endocannabinoid system appears to be unequivocally
involved, either directly or indirectly (through interactions with
other neuromodulators), in the cognitive deficits resulting from
cannabis exposure.57,113 Its dysfunction may be inferred from
cannabinoid challenge studies and research with chronic cannabis
users. Future research utilising CB1 receptor probes and improved
analytic techniques for assessing endocannabinoids in humans125
should enhance our understanding of the role of this system in
cognitive impairment. There are individual differences in response
to cannabis in the short- and long-term, and understanding what
constitutes a susceptibility to greater adverse effects126 must be a
priority for further research. Genetic research will inform specific
vulnerabilities toward the development of cognitive deficits
following exposure to cannabis, as have been identified already in
relation to variations in the catechol-O-methyltransferase (COMT

Val158Met) gene, involved in regulating dopaminergic transmission
and metabolism.127 There is some evidence for structural brain
changes in long-term heavy cannabis users and animal research
continues to explicate the mechanisms of action of cannabinoids
on cognition and brain function. Together, the knowledge gleaned
from these studies will inform not only a greater understanding of
adverse effects of cannabinoids, but the potential for therapeutic
applications of cannabinoids.128 A wealth of integrative data from
multimodal neuroimaging studies of humans is expected to provide
significant advances in this field in coming years.
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